Univercells part of Gates-backed group trying to cut polio vaccine cost

By Gareth Macdonald contact

- Last updated on GMT

iStock/AlexRaths
iStock/AlexRaths
The Bill & Melinda Gates Foundation has granted Univercells $12m (€12.5m) to develop a vaccine manufacturing platform that lowers production costs.

The firm and consortium partners Batavia Biosciences and Natrix Separations have been tasked with radically lowering costs and increasing vaccine availability and affordability in developing countries.

The project will combine Natrix’s chromatography membranes, Batavia’s production capabilities and Univercells’ manufacturing platform, which uses small footprint bioreactors capable of sustaining high cell density cultures.

Univercells told us “This compact design allows significant savings in consumables and operating cost, but also in facility design and construction costs, as the footprint and utilities required to operate this platform are drastically reduced.

“This allows our new platform to manufacture viral vaccines doses at a fraction of the current COGS, with a productivity of 40 million doses per year, and can be adapted to any viral vaccine.”

The Belgian firm told us the first tech transfer to Batavia’s manufacturing site is due to be completed in November 2018.

According to the Gates Foundation, the initial target is to establish a micro-facility for the production of inactivated polio vaccine (sIPV).

Related news

Show more

Related products

show more

High quality excipients and formulation support

High quality excipients and formulation support

Roquette Pharma Solutions | 09-Nov-2021 | Product Brochure

As the world grapples with the effects of ongoing health crises, the market is expanding quickly as developers shift their focus to proactive therapeutics....

Manufacturing of hiPSC-Derived Cardiomyocytes

Manufacturing of hiPSC-Derived Cardiomyocytes

Eppendorf for Bioprocess – Solutions that grow with you | 29-Oct-2020 | Application Note

Effective drug discovery and development relies on the availability of predictive preclinical model systems. Technologies based on human induced pluripotent...

Related suppliers

Follow us

Products

View more

Webinars